Scientific Presentations and Publications

Presentations

July 2023: Hereditary Angioedema Association National Summit

People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as Target for Therapeutic Efficacy

June 2023: European Academy of Allergy and Clinical Immunology Annual Congress

STAR-0215 Bound to Active Plasma Kallikrein Structure Uncovers a New Binding Mode

June 2023: European Academy of Allergy and Clinical Immunology Annual Congress

Design of a Phase 1b/2 Proof-of-Concept Trial of STAR-0215 as a Long-Acting Preventative Therapy in Patients with Hereditary Angioedema (HAE) Types I or II

June 2023: European Academy of Allergy and Clinical Immunology Annual Congress

Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Adult Subjects Followed for 3 Months

May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop

Design of ALPHA-STAR, a Phase 1b/2 proof-of-concept trial of STAR-0215 as a long-acting preventative therapy in patients with hereditary angioedema (HAE) Types I or II

May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop

Mechanistic Modeling and Simulations Predict Long-Term HAE Attack Prevention with STAR-0215

February 2023: AAAAI Annual Meeting

Structure of STAR-0215 Bound to Active Plasma Kallikrein Reveals a Novel Mechanism of Enzyme Inhibition

February 2023: AAAAI Annual Meeting

Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema, in Healthy Adult Subjects Followed for at Least 3 Months

November 2022: ACAAI Annual Scientific Meeting

Modeling and Simulation Predicts Robust HAE Attack Suppression with Every 3 Month Dosing of STAR-0215

July 2022: EAACI Annual Congress

STAR-0215, a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE, Demonstrates Sustained Functional Inhibition in Subcutaneously Dosed Cynomolgus Monkeys

Astria TX on Facebook Astria TX on Twitter Astria TX on LinkedIn Astria TX on Instagram